EV-103: Enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma

KEYNOTE 199 cohorts 4 & 5: Enzalutamide and pembrolizumab for mCRPC

BCG dosing for bladder cancer: Standard frequency schedule correct

RADVAX: Nivolumab / ipilimumab with SBRT for metastatic renal cell carcinoma

CHAARTED: Luminal B subtype as a biomarker of docetaxel benefit for mHSPC

Integrative molecular characterisation of S/R RCC to reveal determinants of poor prognosis and response to ICIs

Cytoreductive nephrectomy for mRCC treated with immune checkpoint inhibitors or targeted therapy

NEO-BLADE: Nintedanib or placebo with gemcitabine and cisplatin in locally advanced muscle invasive bladder cancer

NIVOREN: Nivolumab in a 'real world setting' for metastatic clear-cell renal cell carcinoma

OSPREY: PSMA-targeted PET/CT imaging in prostate cancer patients

Sitravatinib and nivolumab combo for advanced clear cell renal cell cancer

BLASST-1: Combining nivolumab, gemcitabine and cisplatin for the neoadjuvant treatment of muscle invasive bladder cancer

Management of patients with advanced seminoma

CHHip: Conventional versus hypofractionated high-dose intensity modulated radiotherapy for localised prostate cancer

ASCO GU 2020: Updates in renal cancer

Beyond p-values: When does clinical impact outweigh statistical significance?

Prostate-specific membrane antigen PET: Who should undergo advanced imaging?